Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

Several other analysts have also recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday, February 25th. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of Cytosorbents stock opened at $1.00 on Monday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.04. The stock has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp grew its holdings in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares during the last quarter. Skylands Capital LLC grew its holdings in shares of Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Cytosorbents during the 4th quarter valued at approximately $30,000. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.